SETD3 and cancer: Importantly, depletion of endogenous SETD3 in NUDT16-deficient cells did not further exacerbate DNA breaks or enhance the sensitivity of cancer cells to IR treatment, suggesting that the NUDT16-SETD3 pathway might be a promising target for enhancing the sensitivity of cancer cells to radiotherapy in future clinical trials (Fig. 8).